ArticleScientific reports2025
Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the DNA-damaging agents commonly used in clinical settings doxorubicin has emerged as one of the most effective treatments for Triple-negative breast cancer (TNBC). Our limited understanding about the molecular mechanisms underlying the short- and long-term responses of TNBC cells to DNA damage induced by drugs like doxorubicin is a hurdle to improve the efficacy of the treatment or overcome the drug resistance. In this study, we aimed to elucidate the immediate response of the TNBC cells to doxorubicin and compare these responses with those of doxorubicin-resistant cells through transcriptome analysis. Transcriptome analysis revealed that doxorubicin significantly upregulates the expression of TP53 target genes, including CDKN1A, TIGAR, TP53INP1, PPM1D, and ACER2. Notably, doxorubicin-resistant TNBC cells failed to increase the expression of these genes, except for CDKN1A, upon doxorubicin treatment. Moreover, treatment with etoposide as another DNA-damaging drug increased the expression of CDKN1A, TP53INP1, and ACER2 in a TP53-independent manner. Collectively, this study highlights the critical role of TP53 target genes in the immediate response of TNBC cells to DNA-damaging agents like doxorubicin and etoposide. It also reveals distinct molecular mechanisms regulating their expression in resistant versus sensitive cells, offering potential therapeutic targets to improve treatment strategies for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.